PT-141
PT-141 (Bremelanotide)
The only peptide FDA-approved for sexual dysfunction — works centrally on desire, not just blood flow.
Medical Disclaimer: The information on this page is for educational purposes only and does not constitute medical advice. Peptides discussed may be research compounds not approved for human use. Always consult a qualified healthcare provider before starting any peptide protocol. Read our full disclaimer →
Quick Reference
| Peptide Class | Melanocortin receptor agonist |
| Half-Life | ~2.7 hours |
| Administration | Subcutaneous injection, Nasal spray (historical) |
| Typical Dosage | 1.75 mg, 45 minutes before sexual activity |
| Cycle Length | As needed (not daily) |
| Evidence Level | Strong Human Clinical |
| Legal Status | FDA-approved (Vyleesi) for hypoactive sexual desire disorder in premenopausal women — requires prescription |
| Approximate Cost | $100–$300 per dose (brand); $40–$100 per vial (compounded) |
How PT-141 Works
Activates melanocortin MC3R and MC4R receptors in the hypothalamus to enhance sexual desire at the neurological level.
PT-141 acts on melanocortin receptors (MC3R and MC4R) in the hypothalamus — the brain region responsible for regulating sexual desire. Unlike PDE5 inhibitors (Viagra, Cialis) that work peripherally by increasing blood flow to genitalia, PT-141 addresses sexual dysfunction at the central nervous system level. This makes it effective for both men and women, and particularly valuable for individuals whose low libido has a psychological, hormonal, or neurological component rather than a purely vascular one.
Evidence Base
Preclinical Evidence
Animal studies demonstrate dose-dependent increases in sexual behavior and motivation. MC4R activation is well-established as a key mediator of sexual desire.
Human Evidence
FDA-approved based on Phase III trials demonstrating significant improvements in sexual desire and satisfying sexual events in premenopausal women with HSDD. Off-label use in men shows improvements in erectile function and sexual desire.
Anecdotal Evidence
PT-141 has a strong reputation in both men and women for producing reliable, dose-dependent increases in sexual desire. Users describe it as qualitatively different from PDE5 inhibitors — more of a genuine desire enhancement than a mechanical response.
Key PubMed References:
Safety Profile
Side Effects
Nausea (most common, especially at higher doses), flushing, headache, and transient blood pressure elevation. Nausea can be mitigated by starting at lower doses.
Contraindications
Cardiovascular disease (due to transient BP elevation). Not recommended with PDE5 inhibitors due to additive hypotensive effects. Pregnancy.
PeptidePilot Assessment
PT-141 is PeptidePilot's top recommendation for users in the Libido & Sexual Health domain. In our algorithm, it scores highest for users who report low libido as a primary concern, particularly those who have not responded to hormonal interventions alone. Its FDA approval for HSDD gives it a unique credibility advantage over other research peptides in this category.
📊 11% of PeptidePilot users with libido as their primary concern receive PT-141 as their top match
Frequently Asked Questions
Explore More Peptides
The most researched healing peptide for joints, tendons, and gut tissue.
Systemic tissue repair and anti-inflammatory recovery for athletes and injury rehabilitation.
The cleanest growth hormone secretagogue for muscle growth, fat loss, and sleep quality.
Extended-release GHRH analogue that amplifies and sustains growth hormone pulses.
The clinically established GHRH analogue with the longest safety record in anti-aging medicine.
The most clinically validated peptide for weight loss and metabolic health.